Related references
Note: Only part of the references are listed.CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Urvi A. Shah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Cellular immunotherapy in multiple myeloma
Manh-Cuong Vo et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2019)
A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine
Hyun Jin Park et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma
Je-Jung Lee et al.
BLOOD (2019)
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
Je-Jung Lee et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Daratumumab in untreated newly diagnosed multiple myeloma
Nadine Abdallah et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Current Developments in Immunotherapy in the Treatment of Multiple Myeloma
Martin Koehler et al.
CANCER (2018)
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Rosemarie Tremblay-LeMay et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
Manh-Cuong Vo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
Manh-Cuong Vo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
Manh-Cuong Vo et al.
EXPERIMENTAL HEMATOLOGY (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells
Manh-Cuong Vo et al.
ONCOTARGET (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Immunotherapy for the treatment of multiple myeloma
Sung-Hoon Jung et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
T. Jelinek et al.
ONCOIMMUNOLOGY (2016)
Sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells
Cheol Yi Hong et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2016)
Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca2+ transport ATPase 2 regulation
Nu-Ri Choi et al.
CYTOTHERAPY (2015)
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
Thanh-Nhan Nguyen-Pham et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
Manh-Cuong Vo et al.
ONCOTARGET (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Vassiliki A. Boussiotis et al.
CANCER JOURNAL (2014)
Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro
Sung-Hoon Jung et al.
EXPERIMENTAL HEMATOLOGY (2014)
Risk adapted therapy for multiple myeloma: back to basics
Shaji K. Kumar et al.
LEUKEMIA & LYMPHOMA (2014)
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
Tomer M. Mark et al.
LEUKEMIA RESEARCH (2014)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
Lenalidomide enhances anti-myeloma cellular immunity
Katarina Luptakova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Targeting the Tumor Microenvironment for Cancer Therapy
Nor Eddine Sounni et al.
CLINICAL CHEMISTRY (2013)
Pomalidomide: New immunomodulatory agent with potent antiproliferative effects
Paul G. Richardson et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
P. Tassone et al.
CURRENT CANCER DRUG TARGETS (2012)
Mechanism of immunomodulatory drugs in multiple myeloma
Lenka Sedlarikova et al.
LEUKEMIA RESEARCH (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Cellular immunotherapy for multiple myeloma
Jacalyn Rosenblatt et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Robert C. Kane et al.
CLINICAL CANCER RESEARCH (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Dendritic cells as therapeutic vaccines against cancer
J Banchereau et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
